123 related articles for article (PubMed ID: 32748674)
1. Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma.
Tornberg SV; Nisen H; Järvinen P; Järvinen R; Kilpeläinen TP; Taari K; Stenman UH; Visapää H
Scand J Urol; 2020 Oct; 54(5):413-419. PubMed ID: 32748674
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
4. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
6. TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer.
Björkman K; Kaprio T; Beilmann-Lehtonen I; Stenman UH; Böckelman C; Haglund C
Oncology; 2022; 100(1):22-30. PubMed ID: 34794144
[TBL] [Abstract][Full Text] [Related]
7. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
Venesmaa P; Lehtovirta P; Stenman UH; Leminen A; Forss M; Ylikorkala O
Br J Cancer; 1994 Dec; 70(6):1188-90. PubMed ID: 7981075
[TBL] [Abstract][Full Text] [Related]
8. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.
Gaber A; Stene C; Hotakainen K; Nodin B; Palmquist I; Bjartell A; Stenman UH; Jeppsson B; Johnson LB; Jirström K
Radiat Oncol; 2011 Aug; 6():100. PubMed ID: 21864386
[TBL] [Abstract][Full Text] [Related]
9. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
10. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
12. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer.
Venesmaa P; Stenman UH; Forss M; Leminen A; Lehtovirta P; Vartiainen J; Paavonen J
Br J Obstet Gynaecol; 1998 May; 105(5):508-11. PubMed ID: 9637119
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
Lee YC; Pan HW; Peng SY; Lai PL; Kuo WS; Ou YH; Hsu HC
Eur J Cancer; 2007 Mar; 43(4):736-44. PubMed ID: 17267202
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
16. Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma.
Paju A; Jacobsen J; Rasmuson T; Stenman UH; Ljungberg B
J Urol; 2001 Mar; 165(3):959-62. PubMed ID: 11176522
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma.
Lyytinen I; Lempinen M; Nordin A; Mäkisalo H; Stenman UH; Isoniemi H
Scand J Gastroenterol; 2013 Sep; 48(9):1066-73. PubMed ID: 23889187
[TBL] [Abstract][Full Text] [Related]
18. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C
Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
20. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.
Gaber A; Johansson M; Stenman UH; Hotakainen K; Pontén F; Glimelius B; Bjartell A; Jirström K; Birgisson H
Br J Cancer; 2009 May; 100(10):1540-8. PubMed ID: 19384300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
